Securities code: Shanghai Pharmaceuticals Holding Co.Ltd(601607) securities abbreviation: Shanghai Pharmaceuticals Holding Co.Ltd(601607) No.: pro 2022030 Shanghai Pharmaceuticals Holding Co.Ltd(601607)
Announcement of annual profit distribution plan in 2021
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents. Important content tips:
Distribution ratio per share: cash dividend of 4.20 yuan (including tax) for every 10 shares.
The capital stock of this profit distribution is based on the total capital stock registered on the date of equity distribution, and the specific date will be specified in the announcement of equity distribution implementation. If the total share capital of the company changes before the equity registration date of equity distribution, the company plans to keep the distribution amount per share unchanged and adjust the total profit distribution accordingly based on the total share capital on the equity registration date of equity distribution. 1、 Contents of profit distribution plan
Audited by PricewaterhouseCoopers Zhongtian Certified Public Accountants (special general partnership) (hereinafter referred to as “PricewaterhouseCoopers”), as of December 31, 2021, the balance of consolidated undistributed profits of the company was 2859859803467 yuan. According to the resolution of the board of directors, the company plans to distribute profits based on the total share capital registered on the date of equity distribution in 2021. The profit distribution plan is as follows:
The company plans to distribute a cash dividend of 4.20 yuan (including tax) for every 10 shares to all shareholders. As of the date of this announcement, the total share capital including the number of exercised shares of the company’s equity incentive is 2842445936 shares. Based on this calculation, the total amount of cash dividends to be distributed is 11938279312 yuan (including tax), accounting for 23.44% of the consolidated net profit attributable to the shareholders of the listed company in the current year. After distribution, the company’s balance consolidated undistributed profit was 2740477074155 yuan. During the reporting period, no capital reserve will be converted into share capital.
On March 22, 2022, the company received the reply on approving Shanghai Pharmaceuticals Holding Co.Ltd(601607) non-public development of shares issued by China Securities Regulatory Commission, and disclosed the relevant announcement on the same day. Meanwhile, the first batch of options of the company’s 2019 stock option plan are in the vesting period. According to the foregoing, before the equity distribution registration date, the total share capital may change due to non-public offering and equity incentive exercise.
If the total share capital of the company changes between the date of equity distribution and the date of equity registration, the company plans to keep the amount of distribution per share unchanged and adjust the total profit distribution accordingly based on the total share capital on the date of equity distribution. The subsequent company will separately disclose the relevant adjustment announcement according to the actual situation. 2、 Explanation of reasons why the proportion of cash dividends in this year is lower than 30%
With the continuous growth of the company’s business volume and the rapid promotion of innovation, transformation and development strategy, the demand for working capital also increases simultaneously. In order to optimize the company’s capital structure and further improve the company’s ability to provide long-term sustainable returns to all shareholders, the company puts forward the above profit distribution plan in combination with the company’s annual business objectives and capital demand arrangements. 3、 Decision making procedures performed by the company (I), convening, deliberation and voting of the board meeting
The 29th meeting of the seventh board of directors of the company deliberated and approved the 2021 annual profit distribution plan, which needs to be submitted to the 2021 annual general meeting of shareholders of the company for deliberation. (II) opinions of independent directors
The independent directors of the company believe that the profit distribution plan complies with the company law, the self regulatory guidelines for listed companies of Shanghai Stock Exchange No. 1 – standardized operation, the articles of association and other relevant provisions; The review procedure is legal and compliant, and there is no situation that damages the interests of the company and shareholders, especially minority shareholders; After prior approval, the company agreed to the 2021 profit distribution plan and agreed to submit the plan to the general meeting of shareholders for deliberation. (III) opinions of the board of supervisors
The 20th meeting of the 7th board of supervisors of the company deliberated and approved the annual profit distribution plan for 2021, which is considered to be in line with the long-term interests of the company and all shareholders, the current profit distribution policies of the company and the provisions of relevant laws and regulations. 4、 Relevant risk tips
This profit distribution plan will not have a significant impact on the company’s operating cash flow, nor will it affect the company’s normal operation and long-term development.
The profit distribution plan needs to be submitted to the general meeting of shareholders of the company for deliberation. It is hereby announced.
Shanghai Pharmaceuticals Holding Co.Ltd(601607) board of directors
March 30, 2022
